Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting

May 10, 2024

https://www.globenewswire.com/news-release/2024/05/10/2879481/0/en/Editas-Medicine-Preclinical-Data-Highlights-Advancement-of-in-vivo-Gene-Editing-Medicine-Technologies-at-the-American-Society-of-Gene-and-Cell-Therapy-Annual-Meeting.html

Research includes the first-ever application of AsCas12a in vivo, optimized LNP delivery, and gene editing RNA guide modifications

Data to support development of the Company’s in vivo gene editing medicines pipeline  

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.